¹°·Ð, ¹Ì±¹ CDC°¡ Çѱ¹ Á¶Á÷Àº ¾Æ´Ï°í, Çѱ¹ Áúº´°ü¸®Ã»º¸´Ù CDC°¡ ´õ ³´´Ù°í ¸»ÇÒ ¼öµµ ¾øÁö¸¸, ¹Ì±¹ÀÌ Çѱ¹º¸´Ù ¸ÕÀú
Á¢Á¾À» ½ÃÀÛÇß°í, Á¢Á¾ ÄÉÀ̽ºµµ ´õ ¸¹±â ¶§¹®¿¡ Âü°í°¡ µÉ °Í °°½À´Ï´Ù. ´Ù¸¸, ¹Ì±¹ÀÇ °æ¿ì ¾á¼¾ ¹é½ÅÀÌ ½ÂÀÎÀ» ¹Þ¾Ò°í, Çѱ¹Àº
¾Æ½ºÆ®¶óÁ¦³×Ä« ¹é½ÅÀÌ ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ±×·¯³ª ÀÌ µÎ ¹é½ÅÀº ¸ðµÎ ¾Æµ¥³ë¹ÙÀÌ·¯½º º¤ÅÍ ¹é½ÅÀ̱⠶§¹®¿¡ ¾á¼¾¿¡ ¾Æ½ºÆ®¶óÁ¦³×Ä«¸¦
ºñÃ纸½Ã¸é µÉ °Í °°½À´Ï´Ù.
¸¸¾à, ¿©±â ³»¿ë°ú Çѱ¹ Áúº´°ü¸®Ã»ÀÇ Á¤º¸°¡ ¼·Î »óÃæÇÑ´Ù¸é, Çѱ¹ Áúº´°ü¸®Ã»ÀÇ Á¤º¸¸¦ ¿ì¼±À¸·Î ¿©±â½Ã¸é ÁÁ°Ú½À´Ï´Ù. ³ª¶ó¸¶´Ù »óȲÀÌ ´Ù¸£´Ï±î¿ä.
¿ì¼±, ¿ø¹®Àº ¾Æ·¡ ¸µÅ©¿¡¼ º¸½Ç ¼ö ÀÖ½À´Ï´Ù. ³»¿ëÀÌ ±æ¾î¼ ÃÖ´ëÇÑ ÇÊ¿äÇÑ ºÎºÐ¸¸ °£·«ÇÏ°Ô Ã߷ȽÀ´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº °ü·Ã ºÎºÐÀ» Á÷Á¢ º¸½Ã¸é ´õ ¸¹Àº Á¤º¸¸¦ º¸½Ç ¼ö ÀÖ½À´Ï´Ù.
https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html
³»¿ë ÆľÇÀÌ ½¬¿ì½Ãµµ·Ï À½½¿Ã¼·Î ½è½À´Ï´Ù. ¾çÇØ ºÎŹµå¸³´Ï´Ù.
Ȥ½Ã Á¦°¡ ¿µ¾î°¡ ª¾Æ¼ ¹ø¿ªÀÌ À߸øµÈ ºÎºÐÀÌ ÀÖÀ¸¸é, ´ñ±Û·Î ÁöÀûÇØÁÖ½Ã¸é ¹Ù·Î ¼öÁ¤Çϵµ·Ï ÇÏ°Ú½À´Ï´Ù.
[¹é½Å Çã°¡ ¿¬·É]
ÈÀÌÀú ¹é½Å: 16¼¼ ÀÌ»ó
¸ð´õ³ª ¹é½Å: 18¼¼ ÀÌ»ó
¾á¼¾ ¹é½Å: 18¼¼ ÀÌ»ó
[¹é½ÅÁ¢Á¾¹æ¹ý]
ÈÀÌÀú ¹é½Å : 30 ug / 0.3 ml 3ÁÖ°£°Ý 2ȸ
¸ð´õ³ª ¹é½Å : 100 ug / 0.5 ml 4ÁÖ °£°Ý 2ȸ
¾á¼¾ ¹é½Å : 5 X 10
10
¹ÙÀÌ·¯½º ÆÄƼŬ / 0.5 ml 1ȸ
[¹é½Å Á¢Á¾ °£°Ý¿¡ °üÇÏ¿©]
Á¤ÇØÁø 2Â÷ Á¢Á¾ÀϺ¸´Ù 4ÀÏ Àü±îÁö À̸¥ ³¯Â¥¿¡ Á¢Á¾Çصµ À¯È¿, ºÒ°¡ÇÇÇÏ°Ô 2Â÷ Á¢Á¾ÀÌ ´Ê¾îÁø´Ù¸é, ÃÖ°í 6ÁÖ °£°Ý±îÁö µÎ°í 2Â÷ Á¢Á¾ÇÏ¿©µµ À¯È¿.
However,
second doses administered within a grace period of 4 days earlier than
the recommended date for the second dose are still considered valid. If
it is not feasible to adhere to the recommended interval and a delay in
vaccination is unavoidable, the second dose of Pfizer-BioNTech and
Moderna COVID-19 vaccines may be administered up to 6 weeks (42 days)
after the first dose.
[¹é½ÅÀÇ ±³Â÷Á¢Á¾¿¡ ´ëÇØ]
Çã¿ëÇÏÁö ¾ÊÀ½.
COVID-19 vaccines are not interchangeable.
´Ù¸¸, Ưº°ÇÑ °æ¿ì·Î mRNA¹é½ÅÀ» ¸ÂÀº ÈÄ 2Â÷ Á¢Á¾ÀÌ ºÒ°¡´ÉÇÒ °æ¿ì ¾á¼¾ ¹é½ÅÀ» 4ÁÖ ÈÄ¿¡ Á¢Á¾ÇÒ ¼ö ÀÖ´Ù. ÀÌ·² °æ¿ì ¾á¼¾ ¹é½ÅÀ» Á¢Á¾ÇÑ °ÍÀ¸·Î °£ÁÖÇÑ´Ù.
However,
in limited, exceptional situations where a patient received the first
dose of an mRNA COVID-19 vaccine but is unable to complete the series
with either the same or different mRNA COVID-19 vaccine (e.g., due to
contraindication), a single dose of Janssen COVID-19 vaccine may be
considered at a minimum interval of 28 days from the mRNA COVID-19
vaccine dose. ..... Patients who receive Janssen COVID-19 vaccine after a
dose of an mRNA COVID-19 vaccine should be considered to have received a
valid, single-dose Janssen vaccination—not a mixed vaccination series.
[´Ù¸¥ Áúȯ¿¡ ´ëÇÑ ¹é½Å°ú µ¿½Ã¿¡ Á¢Á¾]
´Ù¸¥
Áúȯ¿¡ ´ëÇÑ ¹é½Å(¿¹¸¦µé¸é, ÆÄ»ódz ¹é½Å °°Àº °Å)°ú µ¿½Ã¿¡ Á¢Á¾ÇØ¾ß ÇÑ´Ù¸é Àû¾îµµ 14ÀÏ °£°ÝÀ» µÖ¾ß ÇÑ´Ù. ÇÇÄ¡ ¸øÇÒ
»çÁ¤À¸·Î 14ÀÏ ÀÌ»ó °£°ÝÀ» µÎÁö ¸øÇÏ°í µÎ Á¾·ùÀÇ ´Ù¸¥ ¹é½ÅÀ» Á¢Á¾ÇØ¾ß ÇÑ´Ù°í Çصµ, Äڷγª19 ¹é½ÅÀ» Ãß°¡·Î ¶Ç Á¢Á¾ÇÒ ÇÊ¿ä´Â
¾ø´Ù. (È¿°ú´Â Á» ¶³¾îÁú ¼ö ÀÖÁö¸¸ ¾î¿ ¼ö ¾ø´Ù´Â ÀǹÌ)
[Äڷγª19¿¡ °¨¿°µÇ¾ú´ø »ç¶÷Àº?]
ÀÌÀü °¨¿° ¿©ºÎ¿Í »ó°ü¾øÀÌ ¹é½Å Á¢Á¾À» ¹Þ¾Æ¾ß ÇÔ. ¹é½Å Á¢Á¾ Àü¿¡ °¨¿° ÀÌ·Â Å×½ºÆ®µµ ºÒÇÊ¿äÇÔ. (±×³É ¸ðµÎ ´Ù Á¢Á¾Ç϶ó´Â ÀǹÌ)
People should be offered vaccination regardless of history of prior symptomatic or asymptomatic SARS-CoV-2 infection.
Äڷγª19 ȸº¹ ÈÄ ÃÖ¼Ò ¾ó¸¶°¡ Áö³ª¼ ¹é½ÅÀ» Á¢Á¾ÇØ¾ß ÇÏ´ÂÁöµµ »ó°ü¾øÀ½. (Àç°¨¿°À» ¸·±â À§Çؼ´Â °¡±ÞÀû »¡¸® ¸Â´Â °ÍÀÌ ÁÁ´Ù°í ¾ð±Þ)
While there is no recommended minimum interval between infection and vaccination
[Äڷγª19¿¡ °¨¿°µÇ¾î Ç×üġ·áÁ¦¸¦ ½è´ø »ç¶÷Àº?]
Ç×üÀÇ ¹Ý°¨±â¸¦ °í·ÁÇϸé, Àû¾îµµ 90ÀÏ ÀÌ»ó Áö³ ÈÄ¿¡ ¹é½ÅÀ» Á¢Á¾ÇØ¾ß ÇÔ.
Based
on the estimated half-life of such therapies and evidence suggesting
that reinfection is uncommon in the 90 days after initial infection,
vaccination should be deferred for at least 90 days.
¸¸¾à, 1Â÷ Á¢Á¾À» ÇÑ ÈÄ¿¡ °¨¿°µÇ¾î Ç×üġ·áÁ¦¸¦ »ç¿ëÇßÀ» °æ¿ìµµ, Ç×üġ·áÁ¦¸¦ »ç¿ëÇÑ ÀÌÈÄ 90ÀÏÀÌ Áö³ª¼ 2Â÷ Á¢Á¾À» ÇØ¾ß ÇÔ.
¸¸¾à, Äڷγª19 Ç×üġ·áÁ¦°¡ ¾Æ´Ñ ´Ù¸¥ Áúȯ Ä¡·á ¸ñÀûÀÇ Ç×ü(IVIG, RhoGAM)¸¦ »ç¿ëÇßÀ» °æ¿ì´Â ÀÌ·± Á¦ÇÑ ¾øÀÌ ¹é½ÅÀ» Á¢Á¾ÇÒ ¼ö ÀÖ´Ù.
For
people receiving antibody therapies not specific to COVID-19 treatment
(e.g., intravenous immunoglobulin, RhoGAM), administration of COVID-19
vaccines either simultaneously with or at any interval before or after
receipt of an antibody-containing product is unlikely to substantially
impair development of a protective antibody response. Thus, there is no
recommended minimum interval between antibody therapies not specific to
COVID-19 treatment and COVID-19 vaccination.
[¹é½Å Á¢Á¾ ÈÄ¿¡ Äڷγª19¿¡ °É¸° »ç¶÷]
±âÁ¸ÀÇ Äڷγª19 Ä¡·á¹æ¹ýÀ» ±×´ë·Î Àû¿ëÇÑ´Ù. ¸¸¾à Ç® ¸é¿ªµÈ »ç¶÷ÀÌ Äڷγª19¿¡ È®ÁøµÈ´Ù¸é, »ùÇÃÀ» È®º¸ÇÏ°í VAERS¿¡ º¸°íÇÒ °Í.
[¾Æ³«Çʶô½Ã½º °æÇèÀÚ]
¹é½Å Á¢Á¾À» ±ÇÇÏÁö ¾ÊÀ½.
[È®ÁøÀÚ¿Í ¹ÐÁ¢ Á¢ÃËÀÚ]
ÀÚ°¡ °Ý¸® ±â°£¿¡´Â ¹é½Å Á¢Á¾À» ÇÏÁö ¾Ê´Â´Ù.(È®»êÀÇ ¿ì·Á°¡ ÀÖÀ¸¹Ç·Î) 2Â÷ Á¢Á¾ Àü¿¡ È®ÁøÀÚ¿Í Á¢ÃËÇÏ¿´À» °æ¿ìµµ 2Â÷ Á¢Á¾À» ¹Ì·ï¾ß ÇÑ´Ù.
[¸é¿ªºÎÀüȯÀÚ]
HIV ȯÀÚ³ª ¸é¿ª¾ïÁ¦Á¦¸¦ ¾²´Â »ç¶÷ÀÇ °æ¿ì, µ¥ÀÌÅÍ°¡ ÃæºÐÇÏÁö ¾ÊÀ¸³ª ¹é½ÅÀ» ¾ÈÀüÇÏ°Ô Á¢Á¾ÇÒ ¼ö ÀÖ´Ù.
However,
the currently authorized COVID-19 vaccines are not live vaccines and
therefore can be safely administered to immunocompromised people.
¸é¿ª ¾ïÁ¦ Ä¡·á¸¦ ÇØ¾ß ÇÏ´Â °æ¿ì´Â, ¹é½Å Á¢Á¾À» ¿ÏÀüÈ÷ ³¡³½ ÈÄ 2ÁÖ ÀÌÈÄ¿¡ ÇØ¾ß ÇÑ´Ù.
¸¸¾à ¸é¿ª ¾ïÁ¦ Ä¡·á ½ÃÀÛ 2ÁÖ Àü¿¡ Äڷγª19 ¹é½Å Á¢Á¾À» ¸¶Ä¥ ¼ö ¾ø´Â °æ¿ì¶óµµ, ¹é½ÅÀ» Á¢Á¾ÇÒ ¼ö ÀÖ´Ù.
However,
based on general best practices for vaccination of immunocompromised
people, ideally COVID-19 vaccination should be completed at least two
weeks before initiation of immunosuppressive therapies. When it is not
possible to administer a complete COVID-19 vaccine series in advance,
people on immunosuppressive therapy can still receive COVID-19
vaccination.
Ç׾Ͽä¹ýÀ̳ª ¸é¿ª¾ïÁ¦Á¦¸¦ ¾²´Â µµÁß¿¡ ¹é½ÅÀ» Á¢Á¾ÇÑ °æ¿ì, Ä¡·á°¡ ³¡³ª°í ¸é¿ªÀÌ È¸º¹µÈ ÈÄ¿¡ ¹é½ÅÀ» Àç Á¢Á¾À» ÇÒ ÇÊ¿ä´Â ¾ø´Ù.
[¹é½Å Á¢Á¾ ÈÄ Ç×ü °Ë»ç]
±ÇÇÏÁö ¾ÊÀ½. (±×·¯³ª Àڱ⠵·À¸·Î °Ë»çÇÏ·Á¸é ÇÒ ¼ö´Â ÀÖ½À´Ï´Ù.)
[ÀÚ°¡¸é¿ªÁúȯÀÚ]
¹é½ÅÀÇ È¿°ú³ª ¾ÈÀü¼º¿¡ ´ëÇÑ µ¥ÀÌÅÍ´Â ¾øÀ¸³ª, ¹é½ÅÀÇ ÀÓ»óÅ×½ºÆ®¿¡ ÀÌ·± ȯÀÚµéÀÌ Æ÷ÇԵǾú°í, ¾î¶°ÇÑ ¹®Á¦Á¡µµ ¾ø¾ú´Ù. ¹é½Å Á¢Á¾À» ¹ÞÀ» ¼ö ÀÖ´Ù.
No
imbalances were observed in the occurrence of symptoms consistent with
autoimmune conditions or inflammatory disorders in clinical trial
participants who received COVID-19 vaccine compared to placebo. People
with autoimmune conditions may receive any authorized COVID-19 vaccine.
[±æ·À-¹Ù·¹ ÁõÈıº ÀÌ·Â]
¹é½ÅÀÇ
ÀÓ»óÅ×½ºÆ®¿¡¼ ±æ·À-¹Ù·¹ ÁõÈıºÀÌ º¸°íµÇÁö ¾Ê¾ÒÀ½. ´Ù¸¸, ¾á¼¾ ¹é½Å ÀÓ»óÅ×½ºÆ®¿¡¼´Â ¹é½Å ±×·ì¿¡¼ ÇÑ ¸í, Çöó½Ãº¸ ±×·ì¿¡¼µµ
ÇÑ ¸íÀÌ ¹ß»ýÇÏ¿´À½. µû¶ó¼, ±æ·À-¹Ù·¹ ÁõÈıº ÀÌ·ÂÀÌ ÀÖ´Â »ç¶÷µµ ¹é½ÅÀ» Á¢Á¾ÇÒ ¼ö ÀÖÀ½. ¸¸¾à ¹é½Å Á¢Á¾ ÈÄ ±æ·À-¹Ù·¹
ÁõÈıºÀÌ ³ªÅ¸³ª¸é, VAERS¿¡ º¸°íÇØ¾ß ÇÔ.
People with a history of GBS may receive COVID-19 vaccination.
[¾È¸é½Å°æ¸¶ºñ, ±¸¾È¿Í»ç ÀÌ·Â]
ÀÓ»óÅ×½ºÆ® Áß¿¡ ¾È¸é½Å°æ¸¶ºñ°¡ º¸°íµÇ¾úÀ¸³ª, FDA´Â ÀÚ¿¬ ¹ß»ý ¹üÀ§¸¦ ÃÊ°úÇÏÁö ¾Ê¾Ò´Ù°í ÆÇ´Ü. µû¶ó¼ ¹é½Å Á¢Á¾À» ¹ÞÀ» ¼ö ÀÖ´Ù. ¸¸¾à ¹é½Å Á¢Á¾ ÈÄ ¾È¸é½Å°æ¸¶ºñ°¡ ³ªÅ¸³¯ °æ¿ì VAERS¿¡ º¸°íÇØ¾ß ÇÔ.
In the absence of such evidence, people with a history of Bell¡¯s palsy can receive a COVID-19 vaccine.
[ÇÊ·¯ (filler) ¼ºÇü¼ö¼úÀ» ÇÑ »ç¶÷]
ÇǺΠ¾Æ·¡¿¡ ÇÊ·¯¸¦ ³ÖÀº »ç¶÷ÀÌ mRNA¹é½ÅÀ» Á¢Á¾ ¹ÞÀ¸¸é, ÇÊ·¯¸¦ ÁÖÀÔÇÑ °÷°ú ÁÖº¯ºÎ°¡ º×´Â Çö»óÀÌ ³ªÅ¸³². ÀÌ´Â ÀϽÃÀûÀÎ Çö»óÀ̸ç, ½ºÅ×·ÎÀ̵带 »ç¿ëÇϸé ÇØ°áµÊ. ÁÖÄ¡ÀÇ¿Í »ó´ãÇÏ°í ¹é½ÅÀ» Á¢Á¾ÇÒ ¼ö ÀÖÀ½.
[ÀӽźÎ]
°üÂûµÈ µ¥ÀÌÅÍ¿¡ ÀÇÇϸé, Àӽźΰ¡ Äڷγª19¿¡ °É¸®¸é, ÁßÁõÁúȯÀ¸·Î ÀüÀÌµÉ À§Ç輺ÀÌ ´õ ³ôÀ½.
Àӽźο¡
´ëÇÑ µ¥ÀÌÅÍ°¡ ÃæºÐÇÏÁö ¾ÊÀ¸³ª, ÈÀÌÀú, ¸ð´õ³ª, ¾á¼¾Àº µ¿¹° ½ÇÇèÀ» ÅëÇØ Æ¯º°ÇÑ ¹®Á¦°¡ ¾øÀ½À» Áõ¸íÇÑ ¹Ù ÀÖ´Ù. ´Ù¸¸, ¾á¼¾ÀÇ
°æ¿ì À̹ø Äڷγª19 ¹é½Å°ú ÀÌÀüÀÇ ¿¡º¼¶ó ¹é½ÅÀÇ ÀÓ»óÅ×½ºÆ®¿¡ Àӽźθ¦ Æ÷ÇÔ½ÃÄ×°í, ¾Æµ¥³ë¹ÙÀÌ·¯½º º¤ÅÍ ¹é½ÅÀÌ ¹®Á¦¸¦ ÀÏÀ¸Å°Áö
¾ÊÀ½À» º¸¿´´Ù. (Äڷγª19 ¹é½ÅÀÇ °æ¿ì, ¹é½Å ±×·ì 4¸í, Çöó½Ãº¸ ±×·ì 4¸íÀ» Æ÷ÇÔ½ÃÄ×½À´Ï´Ù. ¸Å¿ì ÀûÀº ¼ýÀÚ¿´½À´Ï´Ù.)
ÇöÀç±îÁöÀÇ Á¤º¸¸¦ Á¾ÇÕÇØ º¼¶§, Àü¹®°¡µéÀÇ °ßÇØ´Â ¹é½ÅÀÌ ÀӽźεéÀÇ À§ÇèÀ» Áõ°¡½ÃÅ°Áö ¾Ê´Â´Ù°í ¹Ï°í ÀÖÀ½.
Based
on current knowledge, experts believe that COVID-19 vaccines are
unlikely to pose a risk to the pregnant person or fetus because the
currently authorized COVID-19 vaccines are non-replicating vaccines and
cannot cause infection in either the mother or the fetus.
ÀӽźδÂ
¹é½ÅÀ» Á¢Á¾ÇÒ ¼ö ÀÖÀ¸¸ç, ÀÇ·áÁø°ú »ó´ãÀ» ÅëÇØ °áÁ¤¿¡ µµ¿òÀ» ¾òÀ» ¼ö ÀÖÀ¸³ª, ÀÌ·± »ó´ãÀ» ¹Þ¾Æ¾ß ¸¸ÀÌ ¹é½Å Á¢Á¾À» ¹ÞÀ» ¼ö
ÀÖ´Â °ÍÀº ¾Æ´Ï´Ù. (ÀÇ·áÁø°ú »ó´ãÇÑ ±â·ÏÀÌ ÀÖ¾î¾ß ¹é½ÅÀ» ¸ÂÀ» ¼ö ÀÖ´Ù´Â Àǹ̰¡ ¾Æ´Ï´Ù¶ó´Â ¶æÀÔ´Ï´Ù.)
Pregnant
people may choose to receive a COVID-19 vaccine. A conversation between
the patient and their clinical team may assist with decisions about the
use of a COVID-19 vaccine, though a conversation with a healthcare
provider is not required before vaccination.
ÀӽŠÁß¿¡ ¹é½Å Á¢Á¾À» °áÁ¤ÇÑ »ç¶÷Àº, v-safe¿¡ °¡ÀÔÇÏ¿© ºÐ¸¸ ¶§±îÁö Ãß°¡ÀûÀÎ °ü¸®¸¦ ¹ÞÀ» ¼ö ÀÖÀ½.
¹é½Å Á¢Á¾ ÈÄ¿¡ ¹ß¿ÀÌ ³ªÅ¸³¯ °æ¿ì ŸÀÌ·¹³îÀ» º¹¿ëÇÒ ¼ö ÀÖÀ½.
°¡Àӱ⠿©¼ºÀÇ °æ¿ì ¹é½Å Á¢Á¾ Àü¿¡ ÀӽŠÁø´Ü Å×½ºÆ®¸¦ º°µµ·Î ÇÒ ÇÊ¿ä´Â ¾øÀ½.
There is no recommendation for routine pregnancy testing before receipt of a COVID-19 vaccine.
[¸ðÀ¯ ¼öÀ¯]
Äڷγª19 ¹é½ÅÀÌ ¸ðÀ¯ ¼öÀ¯¿¡ ¿µÇâÀ» ¹ÌÄ£´Ù´Â Áõ°Å°¡ ¾øÀ½. »ý¹é½ÅÀÌ ¾Æ´Ñ °æ¿ì ¸ðÀ¯ ¼öÀ¯¿¡ À§Ç輺Àº ¾ø´Ù°í ¾Ë·ÁÁ® ÀÖÀ½. µû¶ó¼ ¸ðÀ¯ ¼öÀ¯ ÁßÀÎ ¿©¼ºµµ ¹é½ÅÀ» ¸ÂÀ» ¼ö ÀÖÀ½.
There
are no data on the safety of COVID-19 vaccines in lactating people or
the effects of COVID-19 vaccines on the breastfed infant or milk
production or excretion. Because non-live vaccines pose no risk for
lactating people or their infants, COVID-19 vaccines are also not
thought to be a risk. Therefore, lactating people may choose to be
vaccinated.
[û¼Ò³â, ¾Æµ¿ÀÇ ¹é½Å Á¢Á¾]
16-17¼¼ÀÇ Ã»¼Ò³âÀº ÈÀÌÀú ¹é½ÅÀ» ¸ÂÀ» ¼ö ÀÖÀ½. ¸ð´õ³ª¿Í ¾á¼¾ ¹é½ÅÀº 18¼¼ ÀÌÇÏ´Â Á¢Á¾ÇÒ ¼ö ¾øÀ½.
[¹é½Å Á¢Á¾ ÈÄ]
ÀÇÇÐÀû
¹®Á¦°¡ ¾ø´Ù¸é, ¹é½Å Á¢Á¾ ÈÄ ºÎÀÛ¿ëÀÌ ³ªÅ¸³¯ °æ¿ì ÇØ¿ ÁøÅëÁ¦(¾Æ¼¼Æ®¾Æ¹Ì³ëÆæ, NSAID)¸¦ º¹¿ëÇÒ ¼ö ÀÖ´Ù. ±×·¯³ª, ÀÌ·±
ºÎÀÛ¿ëÀ» ¹æÁöÇϱâ À§ÇØ »çÀü¿¡ ÀÌ·± ¾àÀ» ¹Ì¸® º¹¿ëÇÏ´Â °ÍÀº, ¹é½Å¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡´ÂÁö ¾ÆÁ÷ ¸ð¸£±â ¶§¹®¿¡ ±ÇÀåÇÏÁö ¾Ê´Â´Ù.
For
all currently authorized COVID-19 vaccines, antipyretic or analgesic
medications (e.g., acetaminophen, non-steroidal anti-inflammatory drugs)
can be taken for the treatment of post-vaccination local or systemic
symptoms, if medically appropriate. However, routine prophylactic
administration of these medications for the purpose of preventing
post-vaccination symptoms is not currently recommended, because
information on the impact of such use on COVID-19 vaccine-induced
antibody responses is not yet available.
[Ç×È÷½ºÅ¸¹ÎÁ¦ º¹¿ë]
¾Æ³«Çʶô½Ã½º
¹ßÇöÀ» ¸·±â À§ÇØ, ¹é½Å Á¢Á¾ Àü¿¡ Ç×È÷½ºÅ¸¹ÎÁ¦¸¦ »çÀü¿¡ º¹¿ëÇÏ´Â °ÍÀº ±ÇÀåµÇÁö ¾Ê´Â´Ù. Ç×È÷½ºÅ¸¹ÎÁ¦´Â ¾Æ³«Çʶô½Ã½º¸¦ ¸·¾ÆÁÙ ¼ö
¾øÀ¸¸ç, ¿ÀÈ÷·Á Ç×È÷½ºÅ¸¹ÎÁ¦°¡ ¾Æ³«Çʶô½Ã½º°¡ ³ªÅ¸³ª±â Àü¿¡ º¸¿©Áö´Â ÀüÁ¶ Áõ»óµéÀ» °¡·Á¼ Áø´ÜÀÌ ´Ê¾îÁú ¼ö ÀÖ´Ù.